Direct Meds Review

The verdict: a provider we list as a warning, not a recommendation

Direct Meds is a Utah-based telehealth company selling compounded semaglutide and tirzepatide. We include it here for one reason: so you can see, in plain view, the two things that should give any shopper pause. First, the FDA sent Direct Meds a warning letter in September 2025. Second, its Better Business Bureau profile is full of customers who say they were charged for a three-month supply when they thought they were buying one month. Neither of those is a small footnote. If you read nothing else, read the trust section below before you hand over a card number.

The headline price is $249 a month for sublingual semaglutide, which sits above the category median of $170. On paper the bundle is generous. In practice, the way that bundle gets billed is exactly where the complaints come from.

How the pricing really works — and where it bites

Direct Meds advertises all-inclusive pricing: the medication, the clinician visit, supplies, follow-ups, and one-to-two-day temperature-controlled shipping are all folded into one number. That part is real and, taken alone, is reasonable. The problem is the structure underneath the number.

• Sublingual semaglutide runs $249 a month — the figure quoted in its marketing.
• Injectable semaglutide is priced a step higher than the sublingual drops.
• Tirzepatide, in either the sublingual or injectable format, sits at the top of its menu.
• Plans auto-renew until you cancel by email, and cancellation has to clear the company's retention process.

The recurring theme in BBB reviews is that the advertised monthly figure is not what people were actually charged. Customers describe being billed for a three-month commitment — one verbatim complaint cites a charge of over nine hundred dollars for a three-month supply the buyer says they never agreed to. Whether you read that as a deliberate trap or a badly disclosed default, the result is the same: the price you see is not reliably the price you pay. Confirm the exact billing terms in writing before you order, and assume the commitment is longer than one month unless told otherwise.

The medications: compounded only, in drops or shots

Direct Meds offers both leading GLP-1 molecules — semaglutide and tirzepatide — and, unusually, in both an injectable and a sublingual (under-the-tongue) format. The oral option is the genuine point of difference for needle-averse patients, since most compounding-focused telehealth sells injections only.

Everything here is compounded. There is no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro on the menu. Compounded GLP-1s are made by outsourcing pharmacies rather than the brand manufacturer, and they are not FDA-reviewed for safety or effectiveness the way the brand drugs are. The company names two 503A pharmacy partners — CraftedRx in Missouri and ChemistryRx in Pennsylvania — and holds a LegitScript certification, which are real and worth noting. But certification of the storefront is not the same as the FDA standing behind the product in the vial.

The FDA warning letter you should know about

In September 2025 the FDA issued warning letters to 55 online telehealth companies selling compounded GLP-1 drugs, and Direct Meds was one of them. The specific issue cited in its letter was marketing language — claims like 'same active ingredient as Ozempic and Wegovy' and 'clinically proven ingredients' — that the FDA held to be false or misleading because they imply the compounded product is equivalent to an FDA-approved drug. It isn't.

This matters beyond the legal technicality. It tells you the company was, in the regulator's view, overselling what it actually ships. When you read the rest of its marketing, read it with that in mind.

The review-score gap nobody should ignore

Direct Meds carries a Trustpilot rating of 4.6 out of 5 across thousands of reviews, and a BBB rating of 1.12 out of 5 across 226 reviews. A gap that wide is not noise — it usually signals heavy review solicitation on one platform and a backlog of unresolved disputes on the other. The BBB complaints cluster tightly around the same story: surprise multi-month charges, auto-renewal that's hard to stop, long hold times, and friction when you try to cancel. When two scoreboards disagree this loudly, the one full of detailed, specific complaints is the one to weight.

Who might consider it — and who should walk

There is a narrow case for Direct Meds: someone who specifically wants a sublingual GLP-1, who reads and accepts a multi-month commitment up front, and who is comfortable with compounded medication despite the FDA's marketing objections. For most people, the safer move is a provider without a warning letter and without a documented billing-complaint pattern. If you have insurance or can reach the brand drugs, skip compounded entirely. If you value being able to cancel cleanly, the cancellation friction here is a real and repeated complaint.

Bottom line

Direct Meds bundles a complete GLP-1 program — including a rare oral format — into one all-inclusive monthly price, and it does hold a LegitScript certification with named pharmacy partners. But a September 2025 FDA warning for misleading marketing, a 1.12-out-of-5 BBB rating built on surprise three-month charges, and an auto-renewal model that's hard to exit add up to a profile we list for disclosure rather than recommend. We score its trust low for exactly these reasons; see our scoring methodology for how that's weighed. If you proceed, get the billing terms in writing first, and treat every marketing claim with skepticism.

For a side-by-side, Enhance MD ($212/month) and RxSpan MD ($249/month) are the most comparable options to weigh against Direct Meds.